The composite end point of cardiovascular death and heart failure hospitalization was reduced by 21%, which is highly statistically significant and clinically meaningful, noted Stefan Anker, MD, PhD, FESC, principal investigator of EMPEROR-Preserved.
First-of-their-kind evidence-based results show the composite end point of cardiovascular death and heart failure hospitalization was reduced by 21% with empagliflozin, which is highly statistically significant and clinically meaningful. These are all-around good results for patients with heart failure with preserved ejection fraction (HFpEF), noted Stefan Anker, MD, PhD, FESC, professor of cardiology, Department of Cardiology, Charité Campus Virchow Clinic, Berlin, Germany.
Anker, principal investigator of EMPEROR-Preserved, presented “EMPEROR-Preserved: Effect of Empagliflozin on Cardiovascular Death and Heart Failure Hospitalisations in Patients With Heart Failure With a Preserved Ejection Fraction, With and Without Diabetes” today at ESC Congress 2021, this year’s virtual annual meeting of the European Society of Cardiology.
Transcript
Can you tell us about your presentation on the EMPEROR-Preserved results?
EMPEROR-Preserved is a trial of empagliflozin vs placebo in patients with heart failure and a preserved ejection fraction. Now, your audience should know heart failure with a preserved ejection fraction, that is a very large group of patients—millions and millions of patients worldwide. There’s an estimate saying it's about 20 or 30 million. And so far we have no evidence-based, clear-cut winning trial evidence for any drug to bring about reduction in event rates, bring about benefits to these patients.
Now, we are treating them already, in many cases, with RAAS [renin-angiotensin-aldosterone system] inhibitors or beta-blockers. That is on one hand based on the assumption that we are treating their comorbidities and on the other hand on the assumption that maybe what works in HFrEF [heart failure with reduced ejection fraction] should also work in HFpEF [heart failure with preserved ejection fraction], particularly in the lower ranges of ejection fraction there. But really, in terms of evidence-based medicine that we would like to practice, we have nothing yet. But now we have empagliflozin and the results of EMPEROR-Preserved.
Now, if you look specifically into the results of that trial, in that trial over a period of 26 months of follow-up, recruiting patients with an ejection fraction above 40%, with and without diabetes, 45% of them being women, average ejection fraction in the end 54%, when we follow these patients and look for the primary outcome of cardiovascular death and heart failure hospitalization, we found a 21% reduction, highly statistically significant with a P value of .0003. And this for the first time represents a clinically meaningful and statistically highly significant result in HFpEF patients for any drug ever tested.
Now importantly, the medicine also reduced events regardless of whether or not diabetes was there or not; whether the patients had an ejection fraction between 40% and 50%, 50% and 60%, or above 60%—there was an interaction P value for trend testing of 0.21 for ejection fraction for the primary end point—and also it works basically in men and women with HFpEF. So taken together, looking at these subgroups and other subgroups, we can say that none of the prespecified subgroups tells us anything that there is a subgroup of patients where we shouldn't use this. So in HFpEF patients, empagliflozin represents a medicine that reduces heart outcomes.
If you look specifically for the components of the primary end point, then this is particularly led by a reduction in heart failure hospitalization: first heart failure hospitalization, 29% reduced; first and recurrent heart failure hospitalizations, 27% reduced. Again, highly significant. Cardiovascular mortality, in addition, there is a 9% reduction that doesn't reach significance but it definitely goes in the right direction and contributes overall. And lastly, I would like to add also kidney function is protected. The EGFR [estimated glomerular filtration rate] slope is less declining in patients receiving empagliflozin, quality of life measures improve, and also New York Heart class improves.
So all around good results for the HFpEF patients overall and for all subgroups of them.
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More
Need for Pharmacogenomic Testing in Mental Health Care Explored at AMCP 2024
April 17th 2024Presenters from Mayo Clinic discussed the benefits of implementing pharmacogenomic testing in mental health care for the betterment of patient outcomes, reducing medical costs, and more at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More
Need for Pharmacogenomic Testing in Mental Health Care Explored at AMCP 2024
April 17th 2024Presenters from Mayo Clinic discussed the benefits of implementing pharmacogenomic testing in mental health care for the betterment of patient outcomes, reducing medical costs, and more at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting.
Read More
2 Commerce Drive
Cranbury, NJ 08512